MQS Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

MQS Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,614	Closed	-$250K	–	427
2025 Q3	$250K	Buy	+4,614	New	+$264K	0.15%	312
2024 Q3	–	Sell	-6,818	Closed	-$561K	–	457
2024 Q2	$561K	Buy	+6,818	New	+$568K	0.34%	87
2023 Q4	–	Sell	-4,015	Closed	-$355K	–	472
2023 Q3	$355K	Buy	4,015 +115	+3%	+$10.2K	0.22%	200
2023 Q2	$338K	Sell	3,900 -357	-8%	-$33.6K	0.23%	177
2023 Q1	$414K	Buy	+4,257	New	+$441K	0.27%	141
2022 Q3	–	Sell	-4,374	Closed	-$362K	–	421
2022 Q2	$362K	Sell	4,374 -678	-13%	-$54K	0.25%	169
2022 Q1	$390K	Buy	+5,052	New	+$423K	0.32%	125

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MQS Management's BMRN Position: Q4 2025 in Review

MQS Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,614 shares — an estimated $250K sold.

MQS Management first reported a position in BMRN in Q1 2022 and held it in 7 quarters. The position peaked at $561K in Q2 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

MQS Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
MQS Management sold 4,614 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $250K.
MQS Management first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 7 quarters.
MQS Management's BioMarin Pharmaceuticals position peaked at $561K in Q2 2024.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on MQS Management's 13F filing for Q4 2025, filed 9 Feb 2026.